References
I-194

1. Pharmacy Drug Coverage Policy Manual. North Dakota Department of Health and Human Services. Medical Services Division. http://www.hidesigns.com/ndmedicaid/pdl/
2. Muntoni F, Frank D, Sardone V, et al. Golodirsen induces exon skipping leading to sarcolemmal dystrophin expression in Duchenne Muscular Dystrophy patients with mutations amenable to exon 53 skipping (S22.001). Neuro. 2018;90(15 Supplement).
3. Vyondys 53TM (golodirsen) injection, for intravenous use [package insert].Cambridge, MA. Sarepta Therapeutics, Inc. Revised 2/2021.
4. Clinical Pharmacology™ Compendium. 2022. Tampa FL: Gold Standard, Inc. Golodirsen.
5. Micromedex DrugDex Compendium®. 2022. Golodirsen.
6. Hayes, Inc. Hayes Emerging Technology Report. Vyondys (Golodirsen) for Duchenne Muscular Dystrophy. Lansdale, PA: Hayes, Inc.; December 2019.
7. Golodirsen In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 26, 2021.
8. Institute for Clinical and Economic Review. Deflazacort, eteplirsen, and golodirsen for Duchenne Muscular Dystrophy: effectiveness and value. Final report. August 15, 2019.
9. Blue Cross Blue Shield Association. Treatment for Duchenne Muscular Dystrophy. Medical Policy Reference Manual 05.01.27. Review Date: May, 2021.